BreezeBio Inc. (formerly GeneEdit, hereinafter “BreezeBio”) has won the Grand Prize in the Bio category at the “2026 Korea Industry Awards” for the second consecutive year.

The core reason for this year’s award is the company’s successful completion, early this year, of a KRW 33 billion (USD 25 million) Pre-IPO fundraising round led by Yuanta Investment, with participation from leading domestic venture capital firms, thereby laying the groundwork for a KOSDAQ listing.

The company also changed its name to BreezeBio, reflecting its vision to expand into the development of proprietary therapeutics that apply its gene therapy delivery technologies to actual patients. The new name embodies its determination to bring a fresh breeze to the industry and a wind of hope to patients. Centered on its Pangyo R&D Center, BreezeBio is accelerating the development of therapeutics for autoimmune diseases and cancer vaccines, and its technological capabilities and growth potential have been widely recognized to the extent that the targeted Pre-IPO fundraising amount was fully achieved using only existing investors. Including the Pre-IPO round, the total accumulated investment has reached USD 120 million (approximately KRW 170 billion). Its R&D achievements are also becoming visible. BreezeBio has designated and is developing BRZ-101, a type 1 diabetes treatment based on the principle of antigen-specific immune tolerance (ASIT), as its first clinical program. Related results were first unveiled at an international academic summit last month and drew significant attention.

CEO Lee Geun-woo stated, “We will ensure that many therapeutics are developed through the NanoGalaxy platform so that we can deliver tangible hope to more patients.”

Popular News